Clinical trial NCT03630627: A Phase I Study of SB26 in Healthy Volunteers
Official title: A Randomized, Double-blind, Placebo-controlled, Single and Multiple Rising Dose Study to Explore the Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of SB26 in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Lead sponsor: Samsung Bioepis Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2018-08-15
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a Phase I, randomized double-blind, placebo-controlled (within a dose group), single and multiple rising dose study of the intravenous administration of SB26 in healthy volunteers.

Detailed description: The study includes two Parts; Part 1 includes the FiH exposure and SRD and Part 2 is the MRD. Approximately 58 subjects will be enrolled in the study. New subjects will be recruited for each cohort in both Parts. The SRD Part will include 5 or more dose levels and the MRD Part will include 3 or more dose levels; additional dose level(s) may be added based on emerging safety and PK data from prior cohorts.

Eligibility criteria: Inclusion Criteria:

1. In the opinion of the Investigator, the subject is capable of understanding and complying with protocol requirements.
2. The subject signs and dates a written informed consent form (ICF) and any required privacy authorization prior to the initiation of any study procedures.
3. The subject is willing to comply with study procedures and restrictions.
4. The subject is a healthy adult man or woman of non-childbearing potential.
5. The subject is aged 18 to 65 years, inclusive, at the time of informed consent.
6. The subject weighs at least 50 kg and has a body mass index from 18 to 32 kg/m2, inclusive, at Screening.
7. If the subject is a male who is non-sterilized and who is sexually active with a female partner of childbearing potential, agrees to use adequate contraception from signing of ICF throughout the duration of the study until 60 days (i.e., estimated \> 5 half-lives) after the last dose of study drug(s).
8. The subject is a non-smoker or ex-smoker who has not used tobacco- or nicotine-containing products (e.g., nicotine patch) for at least 6 months prior to first administration of study drug (Day 1) and who has had a negative urine cotinine at Screening and Check-in (Day -1).

Exclusion Criteria:

1. The subject has received any investigational compound or medication within 30 days or five half-lives, whichever is the longest, prior to the first intended dose of study drug.
2. The subject is a study site employee, immediate family member thereof, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, or sibling) or may consent under duress.
3. The subject has a known hypersensitivity to any component of the formulation of SB26, or has had clinically significant infusion-related reactions to any prior biologic drug unless it can be established that the reaction was due to components not present in the formulation of SB26.
4. The subject has a positive urine result for drugs of abuse at Screening or Check-in (Day -1).
5. The subject has a history of drug abuse or a history of alcohol abuse (defined as drinking alcoholic beverages of more than 21 units per week for males and 14 units per week for females; 1 unit = 14 g of pure alcohol, e.g., 1 unit = 250 mL of beer, 25 mL of spirits or one glass \[125 mL\] of wine) within 1 year prior to Screening.
6. If male, the subject intends to father a child or to donate sperm during the course of this study until 60 days after the last dose of study drug.
7. The subject has evidence of current or recent (within 6 months prior to Screening) disease that, in the opinion of the Investigator, may pose additional risks to the subject or confound the assessment of safety and tolerability. This should be discussed with the Sponsor's medical representative if there is uncertainty about the suitability of the subject.
8. The subject has a history of cancer, except basal cell carcinoma or cervical carcinoma in situ that has been treated and in remission for at least 5 years prior to Screening.
9. The subject has a positive test result for hepatitis B surface antigen, hepatitis C virus antibody or human immunodeficiency virus at Screening.
10. The subject has poor peripheral venous access at Screening or Check in (Day -1).
11. The subject has donated or lost 450 mL or more of his or her blood volume (including plasmapheresis) in the 30 days prior to Screening.
12. The subject has an electrocardiogram (ECG) showing a clinically significant abnormality at Screening or Check-in (Day -1). Entry of any subject with an abnormal but not clinically significant ECG must be approved, and documented by signature of the Principal Investigator or a medically qualified sub-Investigator.
13. The subject's ECG has a QT interval with Fridericia correction method \> 450 msec for male, \> 470 msec for female or a PR interval outside the range 120 to 220 msec, confirmed on repeat testing within a maximum of 30 minutes, at Screening or Check-in (Day -1).
14. The subject has a sustained resting heart rate outside the range 40 to 100 beats per minute, confirmed on repeat testing within a maximum of 30 minutes, at Screening or Check-in (Day -1).
15. The subject has systolic blood pressure \> 140 or \< 90 mmHg or a diastolic blood pressure \> 90 or \< 50 mmHg at Screening or Check-in (Day -1). One repeat testing is allowed at Screening and Check-in (Day -1)
16. The subject has any other abnormal laboratory values at Screening or Check-in (Day -1), confirmed upon repeat testing, that suggest a clinically significant underlying disease per the Investigator.

Primary outcomes:
measure: Incidence of TEAE
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Incidence of AE leading to discontinuation
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Abnormal hematology parameters
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Abnormal serum chemistry parameters
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Abnormal coagulation parameters
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Abnormal urinalysis parameters
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Abnormal blood pressure
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Abnormal heart rate
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Abnormal body temperature
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Abnormal ECG
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
Secondary outcomes:
measure: Cmax
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: tmax
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: AUClast
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Vd
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: CL
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: t1/2
timeFrame: Part 1: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: AUCinf
timeFrame: Part 1: From Day 1 until Day 50
measure: Accumulation index
timeFrame: Part 1: From Day 1 until Day 50
measure: AUCtau
timeFrame: Part 2: From Day 1 until Day 71
measure: Accumulation ratio
timeFrame: Part 2: From Day 1 until Day 71
measure: Cmin
timeFrame: Part 2: From Day 1 until Day 71
measure: Incidence of ADA
timeFrame: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Titer of ADAs
timeFrame: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
measure: Incidence of NAb
timeFrame: From Day 1 until Day 50; Part 2: From Day 1 until Day 71
Other outcomes:
Locations:
city: Glendale
country: United States
facility: PAREXEL International
state: California
Study officials:
affiliation: California Clinical Trials Medical Group, a division of PAREXEL International
name: David Han, M.D.
role: PRINCIPAL_INVESTIGATOR
References: